摘要：据报道，富含AT序列特异性结合蛋白(special AT-rich sequence binding protein 2, SATB2)被认为是结直肠癌一种特异性免疫组化标记物；然而，关于SATB2表达与结直肠癌中常见分子改变的关系尚不清楚。我们通过免疫组织化学方法检测了SATB2 在586例消化(gastrointestinal, GI)道和胰腺腺癌中的表达情况以评估其在诊断中的作用，并分析不同SATB2表达的结直肠癌的临床病理和分子特征。我们检测了266例下下GI道来源(246例结直肠癌和20例阑尾黏液腺癌)的腺癌、208例上下GI道和小肠来源(74例起源于食管/食管胃交界处、103例起源于胃、20例起源于十二指肠和11例起源于空回肠)的腺癌及112例胰腺导管腺癌中SATB2和CDX2的表达。与上下GI道、小肠或胰腺来源的腺癌(26/320, 8%)相比，SATB2表达更多见于下下GI道来源的腺癌(222/266, 83%)(P< 0.001)。与CDX2单阳性相比，下下GI道来源的腺癌更特异性呈现SATB2和CDX2的双阳性表达(SATB2+/CDX2+)(94% vs. 57%, P<0.001 )与SATB2阳性表达的结直肠腺癌相比，SATB2阴性表达的结直肠腺癌病例更容易出现MMR蛋白表达缺失(13/39, 33% VS.29/201, 14%, P<0.01)与SATB2表达阳性的肿瘤相比，SATB2表达缺失的肿瘤更容易检出 BRAFV600E 突变(29%vs.3%) (P<0.001)。总之，SATB2表达是下GI道起源肿瘤的相对特异性标志物；然而，SATB2表达的缺失更常见于MMR蛋白缺失和BRAF突変的结直肠癌。
关键词：结直肠癌，SATB2, CDX2, DNA错配修复，BRAF,KRAS
（Am J Surg Pathol 2018;42:1409-1417）
美国外科病理学杂志中文版2019年第2期全文No.2
（蒋 慧 翻译 郑建明 审校）
The American Journal of Surgical Pathology中文版声明：
©2018 Wolters Kluwer Health
The material is published by Wolters Kluwer Health with the permission of American Journal of Surgical Pathology.No part of this publication may be reproduced in any form,stored in a retrieval system or transmitted in any form,by any means,without prior written permission from Wolters Kluwer Health.Opinions expressed by the authors and advertisers are not necessarily those of the American Journal of Surgical Pathology, its affiliates,or of the Publisher.The American Journal of Surgical Pathology,its affiliates,and the Publisher disclaim any liability to any party for the accuracy,completeness,efficacy,or availability of the material contained in this publication (including drug dosages) or for any damages arising out of the use or non-use of any of the material contained in this publication.
Although advertising material is expected to conform to ethical (medical) standards,inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
苏公网安备 32011402010112号